Effects of soy pinitol on the pro-inflammatory cytokines and scavenger receptors in oxidized low-density lipoprotein-treated THP-1 macrophages

Journal of Medicinal Food

Volumn 10, Issue 4, 2007, Pages 594-601

  Choi, Myung Sook ^a   Lee, Won Ha ^a   Kwon, Eun Young ^a   Kang, Mi Ae ^a   Lee, Mi Kyung ^b   Park, Yong Bok ^a   Jeon, Seon Min ^a  

^a Kyungpook National University   (South Korea)

^b Sunchon National University   (South Korea)

Author keywords

Cytokines; Gene expression; Matrix metalloproteinase 9; Oxidized low density lipoprotein; Pinitol; Scavenger receptors; THP 1 macrophages

Indexed keywords

CD36 ANTIGEN; CD68 ANTIGEN; CYTOKINE; GELATINASE B; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; INOSITOL DERIVATIVE; INSULIN; INTERLEUKIN 1BETA; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; OXIDIZED LOW DENSITY LIPOPROTEIN; PINITOL; SCAVENGER RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; DRUG DOSE COMPARISON; FOAM CELL; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LIPID STORAGE; LOW DRUG DOSE; MACROPHAGE; PRIORITY JOURNAL; SOYBEAN;

CELL LINE; CHEMOKINE CCL2; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INOSITOL; INTERLEUKIN-1BETA; INTERLEUKIN-8; LIPIDS; LIPOPROTEINS, LDL; MACROPHAGES; MATRIX METALLOPROTEINASE 9; RECEPTORS, SCAVENGER; RNA, MESSENGER; SOYBEANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 37549062165     PISSN: 1096620X     EISSN: None     Source Type: Journal    
DOI: 10.1089/jmf.2006.220     Document Type: Article

References (57)

1. Glass C, Witztum JL: Atherosclerosis. The road ahead. Cell 2001;104:503-516.
2. Ross R: The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-809.
3. Kelley J: Cytokines of the lung. Am Rev Respir Dis 1990;141:765-788.
4. Bonta IL, Ben Efraim S: Involvement of inflammatory mediators in macrophage antitumor activity. J Leukoc Biol 1993;54:613-626.
5. Belardelli F: Role of interferons and other cytokines in the regulation of the immune response. APMIS 1995;103:161-179.
6. Steinberg D: Arterial metabolism of lipoproteins in relation to atherogenesis. Ann N Y Acad Sci 1990;598:125-135.
7. Steinberg D: Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 1997;272:20963-20966.
8. Barres BA, Hart IK, Coles HS, et al.: Cell death and control of cell survival in the oligodendrocyte lineage. Cell 1992;70:31-46.
9. Wu X, Fan Z, Masui H, Rosen N, Mendelsohn J: Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J Clin Invest 1995;95:1897-1905.
10. Merlo GR, Basolo F, Fiore L, Duboc L, Hynes NE: p53-dependent and p53-independent activation of apoptosis in mammary epithelial cells reveals a survival function of EGF and insulin. J Cell Biol 1995;128:1185-1196.
11. Stout RW, Bierman EL, Ross R: Effect of insulin on the proliferation of cultured primate arterial smooth muscle cells. Circ Res 1975;36:319-327.
12. Pfeifle B, Ditschuneit H: Effect of insulin on growth of cultured human arterial smooth muscle cells. Diabetologia 1981;320:702-706.
13. Stout RW: Development of vascular lesions in insulin-treated animals fed a normal diet. Br Med J 1970;19:685-687.
14. Sato Y, Shiraishi S, Oshida Y, Ishiguro T, Sakamoto N: Experimental atherosclerosis-like lesions induced by hyperinsulinism in Wistar rats. Diabetes 1989;38:91-96.
15. Larner J, Huang LC, Schwartz CF, et al.: Rat liver insulin mediator which stimulates pyruvate dehydrogenase phosphatase contains galactosamine and D-chiroinositol. Biochem Biophys Res Commun 1988;151:1416-1426.
16. Asplin I, Galasko G, Larner J: chiro-Inositol deficiency and insulin resistance: a comparison of the chiro-inositol- and the myo-inositol-containing insulin mediators isolated from urine, hemodialysate, and muscle of control and type II diabetic subjects. Proc Natl Acad Sci U S A 1993;90:5924-5928.
17. Ortmeyer HK, Huang LC, Zhang L, Hansen BC, Larner J: Chiroinositol deficiency and insulin resistance. II. Acute effects of Dchiroinositol administration in streptozotocin-diabetic rats, normal rats given a glucose load, and spontaneously insulin-resistant rhesus monkeys. Endocrinology 1993;132:646-651.
18. Ortmeyer HK, Larne J, Hansen BC: Effects of D-chiroinositol added to a meal on plasma glucose and insulin in hyperinsulinemic rhesus monkeys. Obes Res 1995;3(Suppl):605S-608S.
19. Fonteles MC, Huang LC, Larner J: Infusion of pH 2.0 D- chiroinositol glycan insulin putative mediator mornalizes plasma glucose in streptozotocin diabetic rats at a dose equivalent to insulin without inducing hypoglycemia. Diabetologia 1996;39:731-734.
20. Bates SH, Jones RB, Bailey CJ: Insulin-like effect of pinitol. Br J Pharmacol 2000;130:1944-1948.
21. Narayanan CR, Joshi DD, Mujumdar AM, Dhekne VV: Pinitol - a new anti-diabetic compound from the leaves of Bougainvullea spectabilis. Curr Sci 1987;56:139-141.
22. Concerse CA, Skinner ER: Lipoprotein separation and analysis for clinical studies. In: Lipoprotein Analysis, A Practical Approach. IRL Press at Oxford University Press, New York, 1992, pp. 1-42.
23. Steinbrecher UP: Oxidation of human low density lipoprotein results in derivatization of lysine residues of apolipoprotein B by lipid peroxide decomposition products. J Biol Chem 1987;262:3603-3608.
24. Buege JA, Aust SD: Microsomal lipid peroxidation. Methods Enzymol 1978;52:302-306.
25. Nobel RP: Electrophoretic separation of plasma lipoproteins in agarose gel. J Lipid Res 1968;9:693-700.
26. Trengove NJ, Stacey MC, MacAuley S, et al.: Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors. Wound Repair Regen 1999;7:442-452.
27. Iida KT, Suzuki H, Sone H, et al.: Insulin inhibits apoptosis of macrophage cell line, THP-1 cells, via phosphatidylinositol-3-kinase dependent pathway. Arterioscler Thromb Vasc Biol 2002;22:380-386.
28. Satomi N, Sakurai A, Haranaka K: Relationship of hypoglycemia to tumor necrosis factor production and antitumor activity: role of glucose, insulin, and macrophages. J Natl Cancer Inst 1985;74:1255-1260.
29. Reaven GM: Banting Lecture 1988: role of insulin resistance in human disease. Diabetes 1988;37:1595-1607.
30. Zavaroni I, Bonora E, Pagliara M, et al.: Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. N Engl J Med 1989;320:702-706.
31. Belardelli F: Role of interferons and other cytokines in the regulation of the immune response. Acta Pathol Microbiol Immunol 1995;103:161-179.
32. Iida KT, Suzuki H, Kawakami Y, et al.: Insulin up-regulates tumor mecrosis factor-α production in macrophages through an extracellular-regulated kinase-dependent pathway. J Biol Chem 2001;276:32531-32537.
33. Peraldi P, Spiegelman B: TNF-alpha and insulin resistance: summary and future prospects. Mol Cell Biochem 1978;182:169-175.
34. Jiang C, Ting AT, Seed B: PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998;391:82-86.
35. Jeschke MG, Einspanier R, Klein D: Insulin attenuates the systemic inflammatory response to thermal trauma. Mol Med 2002;8:443-450.
36. Reape TJ, Groot PH: Chemokines and atherosclerosis. Atherosclerosis 1999;147:213-225.
37. Gerard G, Rollins BJ: Chemokines and disease. Nat Immunol 2001;2:108-115.
38. Robinson EA, Yoshimura T, et al.: Complete amino acid sequence of a human monocyte chemoattractant, a putative mediator of cellular immune reactions. Proc Natl Acad Sci U S A 1989;86:1850-1854.
39. Nelken NA, Coughlin SR, Gordon D, Wilcox JN: Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest 1991;88:1121-1127.
40. Takeya M, Yoshimura T, Leonard EJ, Takahashi K: Detection of monocyte chemoattractant protein-1 in human atherosclerotic lesions by an anti-monocyte chemoattractant protein-1 monoclonal antibody. Human Pathol 1993;24:534-539.
41. Bauer J, Berkenbosch F, Van Dam A-M, Dijkstra CD: Demonstration of interleukin-1β in Lewis rat brain during experimental allergic encephalomyelitis by immunohistochemistry at the light and ultrastructural level. J Neuroimmunol 1993;48:13-22.
42. Sairanen TR, Lindsberg PJ, Brenner M, Siren A-L: Global forebrain ischemia results in differential cellular expression of interleukin-1β (IL-1β) and its receptor mRNA and protein level. J Cereb Blood Flow Metab 1997;17:1107-1120.
43. Lee SC, Dickson DW, Brosnan CF: Interleukin-1, nitric oxide and reactive astrocytes. Brain Behav Immun 1995;9:345-354.
44. Wang N, Tabas I, Winchester R, Ravalli S, Rabbani LE, Tall A: Interleukin 8 is induced by cholesterol loading of macrophages and expressed by macrophage foam cells in human atheroma. J Biol Chem 1996;271:8837-8842.
45. Hamilton TA, Ma G, Chisholm GM: Oxidized low density lipoprotein suppresses the expression of tumor-necrosis factor-α mRNA in stimulated murine peritoneal macrophages. J Immunol 1990;144:2343-2350.
46. Thomas CE, Jackson RL, Ohlweiler DF, Ku G: Multiple lipid oxidation products in low density lipoprotein induce interleukin-1 beta release from human blood mononuclear cells. J Lipid Res 1994;35:417-427.
47. Terkeltaub R, Banka CL, Solan J, Santoro D, Brand K, Curtiss LK: Oxidized LDL induces monocytic cell expression of interleukin-8, a chemokine with T-lymphocyte chemotactic activity. Arterioscler Thromb 1994;14:47-53.
48. Brand K, Eisele T, Kreusel U, et al.: Dysregulation of monocytic nuclear factor-kappa B by oxidized low-density lipoprotein. Arterioscler Thromb Vasc Biol 1997;17:1901-1919.
49. Nakata A, Nakagawa Y, Nishida M: CD36, a novel receptor for oxidized low-density lipoproteins, is highly expressed on lipid-laden macrophages in human atherosclerotic aorta. Arterioscler Thromb Vasc Biol 1999;19:1333-1339.
50. Tsukamoto K, Kinoshita M, Kojima K: Synergically increases expression of CD36, CLA-1 and CD68, but not SR-AI and LOX-1, with the progression of foam cells from macrophages. J Atheroscler Thromb 2002;9:57-64.
51. Febbraio M, Podrez EA, Smith JA: Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest 2002;105:1049-1056.
52. Endemann G, Stanton LW, Madden KS, Bryant CM, White RT, Protter AA: CD36 is a receptor for oxidized low-density lipoprotein. J Biol Chem 1993;268:11811-11816.
53. Horvai A, Palinski W, Wu H: Scavenger receptor A gene regulatory elements target gene expression to macrophages and to foam cells of atherosclerotic lesions. Proc Natl Acad Sci U S A 1995;92:5391-5395.
54. Linton MF, Fazio S: Class A scavenger receptors, macrophages, and atherosclerosis. Curr Opin Lipidol 2001;12:489-495.
55. Song E, Ouyang N, Horbelt M, Antus B, Wang M, Exton MS: Influence of alternatively and classically activated macrophages on brogenic activities of human fibroblast. Cell Immunol 2000;204:19-28.
56. Popp O, Heidinger M, Ruiz-Heinrich L, Ries C, Jochum M, Gil-Parrado S: The calpastatin-derived calpain inhibitor CPIB reduces mRNA expression of matrix metalloproteinase-2 and -9 and invasion by leukemic THP-1 cells. Biol Chem 2003;384:951-958.
57. Worley JR, Baugh MD, Hughes DA, et al.: Metalloproteinase expression in PMA-stimulated THP-1 cells. Effects of peroxisome proliferator-activated receptor-gamma (PPAR gamma) agonists and 9-cis-retinoic acid. J Biol Chem 2003;278:51340-51346.